Alzheimer’s Drug Discovery Foundation (ADDF) – Letter of intent

שם: Alzheimer’s Drug Discovery Foundation (ADDF) – Letter of intent
תאריך הגשה: 13/07/18
לאתר הקול הקורא
תיאור כללי:

Preclinical Drug Discovery: focuses on supporting programs that aim to:

Advance novel lead molecules to the clinical candidate selection stage (defined as compounds suitable for IND-enabling studies); or

Build preclinical evidence in relevant animal models for repurposed/repositioned drugs or natural products. Funding: $150,000-$600,000 for 1/2 years.

Program to Accelerate Clinical Trials: Designed to increase the number of novel and repurposed treatments tested in humans for Alzheimer's disease, related dementias and cognitive aging.

This program will fund (1) clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics; (2) proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs*; (3) regulatory studies for investigational new drug (IND)/clinical trial application (CTA) preclinical packages that are required before testing novel drugs in human subjects.

Funding: Up to $3 million.

Biomarkers Development: Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging.

Funding: $150,000-$300,000/year for 1/2 years.

Prevention beyond the pipeline: seeks to support comparative effectiveness research, clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Funding: $50,000-$100,000 for epidemiological analyses based on scope of research

- Up to $3 million based on stage and scope of research

Accelerating Drug Discovery for frontotemporal Degeneration

Seeks to accelerate and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs for FTD through this RFP.

Funding: $100,000-$150,000 for 1 year with potential for follow up funding

Please note: overhead is not covered.

http://www.alzdiscovery.org/research-and-grants/request-for-proposal

מקור: זר
איש קשר: Robi, 2152, robertg@trdf.technion.ac.il; iris 1769, irisbr@trdf.technion.ac.il
תחומים: מדעי החיים ורפואה
סוג הקרן: הקרן אינה קרן תחרותית.
קרן ופרופילים משויכים: Alzheimer’s Drug Discovery Foundation - ADDF ,פתוח לחברי סגל הטכניון בלבד. אנא התחבר\י כדי לצפות בפרופילי המימון של הקרן (בפינה הימנית העליונה).